retatrutide mechanism triple agonist gip glp-1 glucagon retatrutide receptor What GLP‑3 Really Is: Triple‑Receptor Drug Retatrutide for Obesity: Phase 2
Description
Gastrointestinal side effects are a little more common in the oral version than in the injectables
Side Effects: As a GLP-1 therapy, common side effects are typically gastrointestinal, including nausea, vomiting, and diarrhea.
Both human and animal studies reported inconsistent BP response to acute administration but showed hypotensive effect of chronic administration of GLP-1/ GLP-1 RAs
The GLP-1 Receptor Agonist market size is expected to reach $18.32 billion in 2030 at a CAGR of 5.4%, driven by rising prevalence of diabetes.
